# Alnylam Pharmaceuticals, Inc. – Consensus ‘buy’ rating and 37.7% Upside Potential

- Link: https://www.directorstalkinterviews.com/alnylam-pharmaceuticals-inc.consensus-buy-rating-and-37.7-upside-potential/4121127879
- Published: 2023-09-20T14:34:55+01:00
- Author: Charlotte Edwards

**Alnylam Pharmaceuticals, Inc.** which can be found using ticker (ALNY) have now
22 analysts in total covering the stock. The consensus rating is pointing to ‘buy’.
The target price High/Low ranges between 405 and 134 calculating the mean target
price we have $247.55. Now with the previous closing price of $179.77 and the analysts
are correct then there would likely be a percentage uptick in value of 37.7%. The
day 50 moving average is $193.54 and the 200 day moving average is $204.37. The 
company has a market capitalization of 21.96B. The stock price for the company is
currently is currently 175.66 USD

 The potential market cap would be $30,236,540,887 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 10.01 and
a -15.34% return on assets.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The
Company is engaged in developing therapeutics based on ribonucleic acid interference(
RNAi). Its pipeline includes five marketed products and over ten clinical programs,
including several in late-stage development, across four strategic therapeutic areas(
STArs): genetic medicines, cardio-metabolic diseases, hepatic infectious diseases,
and CNS/ocular diseases. Its RNAi-based medicines include ONPATTRO (patisiran), 
AMVUTTRA (vutrisiran), GIVLAARI (givosiran), OXLUMO (lumasiran) and Leqvio (inclisiran).
ONPATTRO is an intravenously administered RNAi therapeutic targeting transthyretin
amyloidosis. GIVLAARI is used to reduce induced liver aminolevulinic acid synthase
1 messenger RNA (mRNA), to reduce toxins associated with attacks and other disease
manifestations of acute hepatic porphyria. OXLUMO is an RNAi therapeutic targeting
hydroxyacid oxidase 1 for the treatment of primary hyperoxaluria type 1.

Share on: